Virtual screening identified Imatinib as a small molecule capable of interacting with the catalytic MPN domain of MYSM1, and this effectively inhibited breast cancer cell growth, highlighting the MYSM1-ERα axis as a promising target to overcome endocrine independence in breast cancer [19]. Here, ESR1 is linked to breast cancer.